Lyka lab micro cap having mcap of 220cr.
As per quarter 1 21-22 result company has repaid 32 CR loan to ARC.
Promoter has released pledge share also.(source BSE disclosure by Company)
Started Job work for Remdesivir drug for reputed Indian pharmaceutical company.(source annual report 20-21) and advertisement on news paper dtd 17.04.21 https://www.lykalabs.com/
Increasing capacity by 50% and ready by second half of current financial year.
Following is abstract of last Annual Report
“To meet the increase in demand for lyophilised products the company has embarked on an expansion project of its Lyophilization Plant at its Ankleshwar factory. This Project is likely to be completed in 9-12 months with a 50% enhancement in capacity for lyophilisation.
Company has received permission to manufacture and marketing of Liposomal Amphotericin B Injection 50 mg/vial from Government of India, Directorate General of Health Services, New Dehi.”
Fail to understand how company can repay loan of 30 CR having turnover of 48 CR for Ist qtr.
If someone having deep knowledge of pharmaceutical sector can throw light on the company?
Can it be considered as fundamental turnaround story.
Invested in last month looking to momentum in the stock though still learning technical analysis.